Transparency Market Research Report Added "Biopharmaceutical Licensing Market" to its database.
Albany, NY -- (SBWIRE) -- 03/22/2016 -- Transparency Market Research presents a new market study, wherein developments in the global biopharmaceutical licensing market are evaluated for the 2012-2018 period. The report, titled "Biopharmaceutical Licensing Market - Global Industry Size, Share, Trends, Analysis, And Forecasts 2012 – 2018," looks into the licensing and alliance aspects of the global biopharma market at length.
This report not only provides valuable insights into market drivers and restraints, but also enumerates the various strategies adopted by biopharma companies to address challenges and convert them into growth opportunities. In addition, a detailed assessment of key trends pertaining to clinical trials and key therapy areas that have been conspicuous in inter-company alliances are presented herein.
In the company profile section of the report, growth strategies of top companies in the biopharmaceutical licensing market are meticulously evaluated. This section also briefs readers about the product pipelines, recent developments, and financial status of top companies in the biopharma market.
The report points out that the biopharma market has undergone a radical change in terms of the regulatory approach for awarding licensing and for alliances that exist between conventional pharma and biopharma companies. This is due to the diminishing conventional differences between pharmaceutical and biopharmaceutical companies. Earlier known for product development or drug discovery, biopharmaceutical companies are currently actively involved in ensuring the sustainability of their products.
Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=318
Due to these endeavors, the biopharmaceutical licensing market is witnessing a marked change. Resultantly, a considerable number of companies in the biopharma sector are focusing on narrowing their portfolio and focusing on high-value therapy areas such as infections, inflammatory disease, and oncology. The biopharmaceutical industry is heading towards attaining complex licensing deals that extend ownership of commercialization rights and marketing revenues for license owners.
Presently, due to changes in the licensing statutes of the biopharma industry, large pharmaceutical companies are intending to enter into in-licensing agreements and alliances with biopharmaceutical companies. The intent is to gain access to advancements and new technologies in molecular science. This is expected to emerge as a major reason for the biopharmaceutical licensing market to reach new heights. The new practice of a tie-up between pharmaceutical and biopharmaceutical companies has increased the consolidation within the biopharma industry to gain a competitive advantage over pharmaceutical companies, which have been traditionally dominant.
In the context of alliances between pharma and biopharma companies, takeovers by Big Pharma are a notable phenomenon, with deal values having risen by at least 80% in recent years.
Top companies that have a significant presence in the global biopharmaceutical licensing market are Pfizer, Intas Pharmaceuticals Ltd., Johnson & Johnson, AstraZeneca, GlaxoSmithKline, Baxter International, Schering-Plough, Proctor & Gamble, Boehringer Inglheim, Merck & Co., Sanofi, Bristol-Myers Squib, Eli Lilly & Company, Hoffman La-Roche, Genentech, Bayer AG, Novartis, and Abbott Laboratories.
Mr. Sudip S
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453